Braveheart Bio, Inc. (BRVE) Stock Price & Analysis

23 Followers

BRVE Stock Chart & Stats

$20.90$1.28(6.52%)

At close: Nov 11 4:00 PM EST

Day’s Range: $19.41 - $21.85
52-Week Range: $16.70 - $32.00
Previous Close: $19.62
Volume: N/A
Average Volume (3M): 412.51K
Market Cap: $1.88B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -1.51
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Braveheart Bio, Inc. News

Braveheart Bio price target raised to $49 from $48 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Braveheart Bio (BRVE) to $49 from $48 and keeps a Buy rating on the shares. The company’s Q3 largely recapped last week’s

12h agoBRVE

Short Report: Core Scientific shorts at four-month highs amid data center fears

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the

3d agoKOD WHR

Braveheart Bio Reports Positive 52-Week HCM Study Data

The latest announcement is out from Braveheart Bio, Inc. ( ($BRVE) ). On November 6, 2026, Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2

5d ago8K BRVE

Braveheart Bio management to meet with Cantor

Meeting to be held in Chicago on November 6 hosted by Cantor. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’

6d agoBRVE

Braveheart Bio falls -13.9%

Braveheart Bio (BRVE) is down -13.9%, or -$4.06 to $25.14. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks

1M agoBRVE

The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’

The past several years saw muted IPO activity, a generally negative signal for market health. But 2026 has reversed that trend. Yes, you can say that the June IPO of

2M agoBRVE LTGO

Midday Fly By: Aon buying USI, Lilly to acquire Merida

The major averages were broadly lower near noon as higher oil prices added to inflation risks and consolidated concerns of an incoming rate hike by the Federal Reserve. The pullback

2M agoDE GM

Deere upgraded, Lumentum initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

2M agoDE TP

Cantor starts Braveheart at Overweight on favorable setup into data

Cantor Fitzgerald initiated coverage of Braveheart Bio (BRVE) with an Overweight rating and $40 price target The firm sees “plenty to play for from here” despite the stock’s recent rally.

2M agoBRVE

Braveheart Bio initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Olivia Brayer Saunders initiated coverage of Braveheart Bio (BRVE) with an Overweight rating and $40 price target Published first on TheFly – the ultimate source for real-time,

2M agoBRVE

Braveheart Bio initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Braveheart Bio (BRVE) with a Buy rating and no price target The company’s BHB-1893 has generated one of the most differentiated cardiac myosin inhibitor datasets

2M agoBRVE

Braveheart Bio initiated with a Buy at Jefferies

Jefferies initiated coverage of Braveheart Bio (BRVE) with a Buy rating and $48 price target The two Phase II datasets from the company’s China partner Hengrui suggest BHB-1893 could be

2M agoBRVE

TipRanks Analyst Salveen Richter Reiterates Buy on Braveheart Bio, Sets $48 12-Month Target on Strong HCM Opportunity for Lead Asset BHB-1893

Braveheart Bio, Inc. (BRVE) has received a new Buy rating, initiated by Goldman Sachs analyst, Salveen Richter. Salveen Richter has given his Buy rating due to a combination of factors

2M agoBRVE

BRVE FAQ

What was Braveheart Bio, Inc.’s price range in the past 12 months?

Braveheart Bio, Inc. lowest stock price was $16.70 and its highest was $32.00 in the past 12 months.

What is Braveheart Bio, Inc.’s market cap?

Braveheart Bio, Inc.’s market cap is $1.88B.

When is Braveheart Bio, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Braveheart Bio, Inc.’s earnings last quarter?

Braveheart Bio, Inc. released its earnings results on Nov 10, 2026. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.438 by -$0.072.

Is Braveheart Bio, Inc. overvalued?

According to Wall Street analysts Braveheart Bio, Inc.’s price is currently Undervalued.

Does Braveheart Bio, Inc. pay dividends?

Braveheart Bio, Inc. does not currently pay dividends.

What is Braveheart Bio, Inc.’s EPS estimate?

Braveheart Bio, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Braveheart Bio, Inc. have?

Braveheart Bio, Inc. has 90,038,970 shares outstanding.

What happened to Braveheart Bio, Inc.’s price movement after its last earnings report?

Braveheart Bio, Inc. reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.438. Following the earnings report the stock price went up 6.524%.

Which hedge fund is a major shareholder of Braveheart Bio, Inc.?

Currently, no hedge funds are holding shares in BRVE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Braveheart Bio, Inc. Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description